Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

ABSTRACT The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15–136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202–10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8–15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals.

[1]  K. Thiagarajan What do we know about India’s Covaxin vaccine? , 2021, BMJ.

[2]  J. V. Van Eyk,et al.  Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 , 2021, Nature Medicine.

[3]  T. Pastinen,et al.  Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.

[4]  D. Vézina,et al.  A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses , 2021, bioRxiv.

[5]  V. Simon,et al.  Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine , 2021, The New England journal of medicine.

[6]  M. Sajadi,et al.  Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. , 2021, JAMA.

[7]  J. Moon,et al.  Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals , 2021, The Lancet.

[8]  Jonathan C. Brown,et al.  Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine , 2021, The Lancet.

[9]  A. Soysal,et al.  Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19. , 2021, Journal of infection in developing countries.

[10]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[11]  K. Chu,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2020, The Lancet Infectious Diseases.

[12]  A. Anarat,et al.  The Use of Social Network in Daily Pediatric Practice and Education: Turkish Pediatric Atelier , 2020, International Journal of Pediatrics.